MedPath

Glyburide

Generic Name
Glyburide
Brand Names
Diabeta, Glucovance, Glynase, Amglidia
Drug Type
Small Molecule
Chemical Formula
C23H28ClN3O5S
CAS Number
10238-21-8
Unique Ingredient Identifier
SX6K58TVWC
Background

Glyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II. It is typically given to patients who cannot be managed with the standard first line therapy, metformin. Glyburide stimulates insulin secretion through the closure of ATP-sensitive potassium channels on beta cells, raising intracellular potassium and calcium ion concentrations.

Glyburide was granted FDA approval on 1 May 1984. A formulation with metformin was granted FDA approval on on 31 July 2000.

Indication

Glyburide is indicated alone or as part of combination product with metformin, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.

Associated Conditions
Gestational Diabetes Mellitus (GDM), Glycemic Control, Type 2 Diabetes Mellitus

Oral Antidiabetic Agents in Pregnancy

Phase 4
Conditions
Gestational Diabetes
Interventions
First Posted Date
2014-03-19
Last Posted Date
2014-03-19
Lead Sponsor
Hospital de Clinicas de Porto Alegre
Target Recruit Count
80
Registration Number
NCT02091336
Locations
🇧🇷

Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil

A Feasibility Study Looking at the Use of Glibenclamide and metfoRmin Versus stAndard Care in gEstational diabeteS

Phase 3
Completed
Conditions
Pregnancy
Gestational Diabetes
Interventions
First Posted Date
2014-03-06
Last Posted Date
2016-12-08
Lead Sponsor
University of Edinburgh
Target Recruit Count
23
Registration Number
NCT02080377
Locations
🇬🇧

St Johns Hospital, Livingston, West Lothian, United Kingdom

🇬🇧

Princess Royal Infirmary, Glasgow, Lanarkshire, United Kingdom

🇬🇧

Western General Hospital, Edinburgh, Lothian, United Kingdom

and more 2 locations

Glyburide and Metformin for the Treatment of Gestational Diabetes Mellitus. Systematic Review

First Posted Date
2013-11-28
Last Posted Date
2015-03-24
Lead Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Target Recruit Count
2509
Registration Number
NCT01998113
Locations
🇪🇸

Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Glycemic Profile in Women With Gestational Diabetes Treated With Glyburide

Phase 4
Withdrawn
Conditions
Gestational Diabetes
Interventions
Device: Continuous glucose monitor
First Posted Date
2013-09-20
Last Posted Date
2016-05-11
Lead Sponsor
University of Pittsburgh
Registration Number
NCT01947699
Locations
🇺🇸

Magee Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States

Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes

Phase 3
Completed
Conditions
Type 2 Diabetes
Interventions
First Posted Date
2013-04-02
Last Posted Date
2017-08-02
Lead Sponsor
Azienda Ospedaliero-Universitaria di Parma
Target Recruit Count
64
Registration Number
NCT01822548
Locations
🇮🇹

Azienda Opedaliera-Universitaria, Parma, Italy

🇮🇹

Azienda Ospedaliera-Universitaria, Parma, Italy

Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals

Phase 2
Completed
Conditions
Ischemic Stroke
Malignant Edema
Interventions
First Posted Date
2013-02-18
Last Posted Date
2024-11-12
Lead Sponsor
Remedy Pharmaceuticals, Inc.
Target Recruit Count
86
Registration Number
NCT01794182
Locations
🇺🇸

University of Maryland School of Medicine, Baltimore, Maryland, United States

🇺🇸

UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States

🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

and more 14 locations

Multicenter Randomized Trial of Non-inferiority Between Glyburide and Insulin for the Treatment of Gestational Diabetes

Phase 3
Completed
Conditions
Gestational
Diabetes
Interventions
Other: Insulin
First Posted Date
2012-11-21
Last Posted Date
2017-12-08
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
914
Registration Number
NCT01731431
Locations
🇫🇷

Marie-Victoire Senat, Paris, France

Glyburide Healthy Volunteer Study

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Placebo
First Posted Date
2012-10-29
Last Posted Date
2014-09-16
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
21
Registration Number
NCT01716338
Locations
🇺🇸

Washington University in St. Louis Clinical Research Unit (CRU), St. Louis, Missouri, United States

Efficacy of Repaglinide in Subjects With Type 2 Diabetes

Phase 4
Completed
Conditions
Diabetes
Diabetes Mellitus, Type 2
Interventions
First Posted Date
2012-10-03
Last Posted Date
2017-02-20
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
9
Registration Number
NCT01698931
Locations
🇮🇹

Novo Nordisk Investigational Site, Padova, Italy

© Copyright 2025. All Rights Reserved by MedPath